Overall, this study enhances our understanding of the use of natural compounds for the targeted treatment of clinical diseases, implying that the co-mediation of the negative regulator KLF15 with natural compounds may be an entirely new therapeutic strategy for cardiomyopathy treatment in the future. This evidence concerns the gene KLF15 and cardiomyopathy.